The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3- azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 1111-1126

  Tizzano, Joseph P ^a   Stribling, D Sloan ^c   Perez Tilve, Diego ^b   Strack, Alison ^c   Frassetto, Andrea ^c   Chen, Richard Z ^c   Fong, Tung M ^c   Shearman, Lauren ^c   Krieter, Philip A ^a   Tschöp, Matthias H ^b   Skolnick, Phil ^a   Basile, Anthony S ^a  

^a DOV Pharmaceutical Inc   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0] HEXANE HYDROCHLORIDE; DEXFENFLURAMINE; DOV 21947; NEUROTRANSMITTER UPTAKE INHIBITOR; SIBUTRAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BREATHING RATE; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ELECTROCARDIOGRAM; HEART RATE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SYNAPTOSOME; TIDAL VOLUME;

ANIMALS; ANTI-OBESITY AGENTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BODY WEIGHT; CARDIOVASCULAR SYSTEM; DIETARY FATS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED C57BL; NEUROTRANSMITTER UPTAKE INHIBITORS; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; WEIGHT GAIN;

EID: 40849137941     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.133132     Document Type: Article

References (41)

1. Alex KD and Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320.
2. Arterburn DE, Crane PK, and Veenstra DL (2004) The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164:994-1003.
3. Balcioglu A and Wurtman RJ (2000) Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology 39:2352-2359.
4. Billes SJ and Cowley MA (2007) Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 32:822-834.
5. Christensen R, Kristensen PK, Bartels EM, Bliddal H, and Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet 370:1706-1713.
6. Comings DE and Blum K (2000) Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 126:325-341.
7. Ericsson M, Poston WCS, and Foreyt JP (1996) Common biological pathways in eating disorders and obesity. Addict Behav 21:733-743.
8. Gabriely I, Ma X-H, Yang X-M, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, and Barzilai N (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging. Diabetes 51:2951-2958.
9. Gadde KM and Xiong GL (2007) Bupropion for weight reduction. Expert Rev Neurother 7:17-24.
10. Gadde KM, Yonish GM, Wagner HR 2nd, Foust MS, and Allison DB (2006) Atomoxetine for weight reduction in obese women: a preliminary randomized controlled trial. Int J Obes (Lond) 30:1138-1142.
11. Gasteyger C and Tremblay A (2002) Metabolic impact of body fat distribution. J Endocrinol Invest 25:876-883.
12. Gehlert DR, Dreshfield L, Tinsley F, Benvenga MJ, Gleason S, Fuller RW, Wong DT, and Hemrick-Luecke SK (1998) The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding. J Pharmacol Exp Ther 287:122-127.
13. Hainer V, Kabrinova K, Aldhoon B, Kunesova M, and Wagenknecht M (2006) Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann N Y Acad Sci 1083:252-269.
14. Heal D, Aspley S, Prow MR, Jackson HC, Martin K, and Cheetham SC (1998) Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes (Lond) 22:S18-S28.
15. Heinrichs SC (2003). Nonexercise muscle tension and behavioral fidgeting are positively correlated with food availability/palatability and body weight in rats. Physiol Behav 79:199-207.
16. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, and Hunter GA (1989) Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior: theoretical and clinical implications. Ann N Y Acad Sci 575:171-191.
17. Horvath TL (2005) The hardship of obesity: a soft-wired hypothalamus. Nat Neurosci 8:561-565.
18. Kelley AE, Baldo BA, Pratt WE, and Will MJ (2005) Corticostriatal- hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 86:773-795.
19. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, and Pollmächer T (2002) Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35:220-225.
20. Leibowitz SF (1992) Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci 15:491-497.
21. Levine JA, Eberhardt NL, and Jensen MD (1999) Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 283:212-214.
22. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, et al. (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Int Med 142:532-546.
23. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, and Hudson JI (2007) Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 68:390-398.
24. Meguid MM, Fetissov SO, Varma M, Sato T, Zhang L, Laviano A, and Rossi-Fanelli F (2000) Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 16:843-857.
25. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, and Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76-79.
26. Moser VC (2000) The functional observational battery in adult and developing rats. Neurotoxicology 21:989-996.
27. Navailles S, Moison D, Ryczko D, and Spampinato U (2006) Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors. J Neurochem 99:1311-1319.
28. Nelson DL and Gehlert DR (2006) Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 29:49-60.
29. 2C) receptor agonists as potential anti-obesity agents. J Med Chem 49:4023-4034.
30. Nonogaki K (2000) New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43:533-549.
31. Patel PN and Pathak R (2007) Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 64:481-489.
32. Sachdev M, Miller WC, Ryan T, and Jollis JG (2002) Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 144:1065-1073.
33. Skolnick P and Basile AS (2007) Triple reuptake inhibitors ("broad spectrum" antidepressants). CNS Neurol Disord Drug Targets 6:141-149.
34. Skolnick P, Popik P, Janowsky A, Beer B, and Lippa AS (2003) Antidepressant-like actions of DOV 21947: a "triple" reuptake inhibitor. Eur J Pharmacol 461:99-104.
35. Smith RG, Innes JA, and Munro JF (1975) Double-blind evaluation of mazindol in refractory obesity. Br Med J 3:284.
36. Van de Water A, Verheyen J, Xhonneux R, and Reneman RS (1989) An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Meth 22:207-217.
37. Wang G-J, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, and Fowler JS (2001) Brain dopamine and obesity. Lancet 357:354-357.
38. Wise RA (2006) Role of brain dopamine in food reward and reinforcement. Philos Trans R Soc Lond B Biol Sci 361:1149-1158.
39. Wise TN, Perahia DG, Pangallo BA, Losin WG, and Wiltse CG (2006) Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 8:269-278.
40. Woolard J, Bennett T, Dunn WR, Heal DJ, Aspley S, and Gardiner SM (2004) Acute cardiovascular effects of sibutramine in conscious rats. J Pharmacol Exp Ther 308:1102-1110.
41. Yen TT and Fuller RW (1992) Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss. Am J Clin Nutr 55 (Suppl 1):177S-180S.